[go: up one dir, main page]

CL2011002662A1 - Preparacion solida que comprende i) acido y ester de 2 - etoxi- 1 - (ciclohexiloxicarboniloxi)etil-2-etoxi-1-[[2-(1h-tetrazol- 5- il) bifenil-4-il]bifenil-4-]metil]bencimidazol-7-carboxilico, acido y 2-etoxi- 1-[[2-(4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1h-bencimidazol-7- carboxilico, ii) manitol, y iii) amlodipino. - Google Patents

Preparacion solida que comprende i) acido y ester de 2 - etoxi- 1 - (ciclohexiloxicarboniloxi)etil-2-etoxi-1-[[2-(1h-tetrazol- 5- il) bifenil-4-il]bifenil-4-]metil]bencimidazol-7-carboxilico, acido y 2-etoxi- 1-[[2-(4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1h-bencimidazol-7- carboxilico, ii) manitol, y iii) amlodipino.

Info

Publication number
CL2011002662A1
CL2011002662A1 CL2011002662A CL2011002662A CL2011002662A1 CL 2011002662 A1 CL2011002662 A1 CL 2011002662A1 CL 2011002662 A CL2011002662 A CL 2011002662A CL 2011002662 A CL2011002662 A CL 2011002662A CL 2011002662 A1 CL2011002662 A1 CL 2011002662A1
Authority
CL
Chile
Prior art keywords
biphenyl
ethoxy
methyl
benzimidazol
carboxylic acid
Prior art date
Application number
CL2011002662A
Other languages
English (en)
Inventor
Wataru Hoshina
Makota Fukuta
Shigeyuki Marunaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002662(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2011002662A1 publication Critical patent/CL2011002662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Preparación sólida que comprende: i) Compuestos derivados de 1-(bifenil-4-il-metil)-bencimidazol, ii) Un alcohol de azúcar y iii) Un antagonista de calcio.
CL2011002662A 2009-04-30 2011-10-26 Preparacion solida que comprende i) acido y ester de 2 - etoxi- 1 - (ciclohexiloxicarboniloxi)etil-2-etoxi-1-[[2-(1h-tetrazol- 5- il) bifenil-4-il]bifenil-4-]metil]bencimidazol-7-carboxilico, acido y 2-etoxi- 1-[[2-(4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1h-bencimidazol-7- carboxilico, ii) manitol, y iii) amlodipino. CL2011002662A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009111381 2009-04-30
JP2010068625 2010-03-24

Publications (1)

Publication Number Publication Date
CL2011002662A1 true CL2011002662A1 (es) 2012-06-15

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002662A CL2011002662A1 (es) 2009-04-30 2011-10-26 Preparacion solida que comprende i) acido y ester de 2 - etoxi- 1 - (ciclohexiloxicarboniloxi)etil-2-etoxi-1-[[2-(1h-tetrazol- 5- il) bifenil-4-il]bifenil-4-]metil]bencimidazol-7-carboxilico, acido y 2-etoxi- 1-[[2-(4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1h-bencimidazol-7- carboxilico, ii) manitol, y iii) amlodipino.

Country Status (24)

Country Link
EP (1) EP2424501A2 (es)
JP (1) JP5666471B2 (es)
KR (1) KR101797776B1 (es)
CN (1) CN102481248B (es)
AU (1) AU2010242308A1 (es)
BR (1) BRPI1014388A2 (es)
CA (1) CA2760073A1 (es)
CL (1) CL2011002662A1 (es)
CO (1) CO6470841A2 (es)
CR (1) CR20110581A (es)
DO (1) DOP2011000329A (es)
EA (1) EA201171329A1 (es)
EC (1) ECSP11011494A (es)
GE (1) GEP20135940B (es)
IL (1) IL215962A0 (es)
MA (1) MA33280B1 (es)
MX (1) MX2011011011A (es)
MY (1) MY158158A (es)
NZ (1) NZ596395A (es)
PE (1) PE20120315A1 (es)
SG (1) SG175794A1 (es)
TW (1) TWI438201B (es)
WO (1) WO2010126168A2 (es)
ZA (1) ZA201108375B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
KR101535586B1 (ko) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 무정형 또는 열역학적 준 안정형 리바록사반을 포함하는 약학 제제
KR101806004B1 (ko) * 2015-01-30 2017-12-08 씨제이헬스케어 주식회사 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물
CN106668016B (zh) * 2015-11-11 2020-06-23 江苏先声药业有限公司 阿齐沙坦和苯磺酸氨氯地平组合物的固体制剂及其制备方法
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法
JP2019001782A (ja) * 2017-06-14 2019-01-10 東和薬品株式会社 二層錠
JP7101464B2 (ja) * 2017-09-28 2022-07-15 エルメッド株式会社 アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法
CN108210472A (zh) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 一种西尼地平固体分散体片剂及其制备方法
CN108685925B (zh) * 2018-05-15 2019-12-06 徐州医科大学 一种化合物AB-38b在制备治疗糖尿病肾病药物方面的应用
JP2020075869A (ja) * 2018-11-05 2020-05-21 日本ケミファ株式会社 カルシウム拮抗剤及びアンジオテンシンｉｉ受容体拮抗剤を有効成分として含有する錠剤
JP7206872B2 (ja) * 2018-12-07 2023-01-18 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP7441105B2 (ja) * 2020-03-31 2024-02-29 日本ジェネリック株式会社 アジルサルタン及びアムロジピンベシル酸塩を含有するフィルムコーティング錠

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
WO2003047573A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4743684B2 (ja) * 2002-05-22 2011-08-10 塩野義製薬株式会社 難水溶性薬物の溶出性を改善する方法
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP2006321726A (ja) * 2005-05-17 2006-11-30 Sysmex Corp 錠剤の溶出性調整方法
WO2007001065A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Method for the preparation of a wet granulated drug product
CN101247832B (zh) * 2005-06-27 2011-12-28 第一三共株式会社 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
MX351987B (es) * 2007-03-29 2017-11-03 Daiichi Sankyo Co Ltd Composicion farmaceutica.
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida

Also Published As

Publication number Publication date
ECSP11011494A (es) 2011-12-30
KR20120026060A (ko) 2012-03-16
CN102481248B (zh) 2013-12-11
BRPI1014388A2 (pt) 2016-04-05
MA33280B1 (fr) 2012-05-02
ZA201108375B (en) 2013-01-30
PE20120315A1 (es) 2012-04-07
WO2010126168A2 (en) 2010-11-04
JP2012525323A (ja) 2012-10-22
CR20110581A (es) 2012-01-19
TW201041873A (en) 2010-12-01
AU2010242308A1 (en) 2011-12-01
NZ596395A (en) 2013-06-28
EA201171329A1 (ru) 2012-05-30
GEP20135940B (en) 2013-10-10
DOP2011000329A (es) 2011-11-15
TWI438201B (zh) 2014-05-21
MY158158A (en) 2016-09-15
JP5666471B2 (ja) 2015-02-12
CO6470841A2 (es) 2012-06-29
CN102481248A (zh) 2012-05-30
IL215962A0 (en) 2012-01-31
MX2011011011A (es) 2011-11-02
EP2424501A2 (en) 2012-03-07
KR101797776B1 (ko) 2017-11-14
WO2010126168A3 (en) 2011-03-03
SG175794A1 (en) 2011-12-29
CA2760073A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
CL2011002662A1 (es) Preparacion solida que comprende i) acido y ester de 2 - etoxi- 1 - (ciclohexiloxicarboniloxi)etil-2-etoxi-1-[[2-(1h-tetrazol- 5- il) bifenil-4-il]bifenil-4-]metil]bencimidazol-7-carboxilico, acido y 2-etoxi- 1-[[2-(4,5-dihidro-5-oxo-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1h-bencimidazol-7- carboxilico, ii) manitol, y iii) amlodipino.
HUP1300730A2 (en) A method of preparing 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl- 4-yl)methyl)-1h-benzo[d]imidazole-7-carboxylates and conversion thereof to azilsartan
AR094588A2 (es) Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica
WO2012107814A8 (en) An improved process for the preparation of azilsartan medoxomil
FR18C1020I2 (fr) Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
DK3170818T3 (da) Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
WO2009147170A3 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
PE20190342A1 (es) Combinaciones de compuestos activos
CL2013000768A1 (es) Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa.
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
EP2331784A4 (en) LOCK COUPLING FOR BOHRLOCHMOTOR
BRPI1008920A2 (pt) Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
EP2340404A4 (en) HIGH PRESSURE CONTROL FOR A TRANSCRITICAL REFRIGERATION SYSTEM
DK2094694T3 (da) Quiniclidinderivater af (hetero)acrylcycloheptancarboxylsyre som muskarin-receptorantagonister
IL228153A0 (en) A method for the production of 2-ethoxy-1-((2'-((hydroxyamino)iminomethyl)biphenyl-4-yl)methyl)-h1-benzo [di]imidazole-7 carboxylic acid, and its esters
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
BRPI0821315A2 (pt) compostos benzimidazol
EA201390457A1 (ru) Полиморфы и соли 6-(1h-индол-4-ил)-4-(5-{[4-(1-метилэтил)-1-пиперазинил]метил}-1,3-оксазол-2-ил)-1h-индазола в качестве ингибиторов pi3k для применения в лечении, например, респираторных расстройств
CL2011000138A1 (es) Uso de compuestos acido 1-{4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxiimino)-etil-2-etil-bencil}-azetidin-3-carboxilico para la preparacion de un medicamento para prevenir, inhibir o tratar una condicion inflamatoria seleccionada de polimiositis o dermatomiositis.
EP2521721A4 (en) 3- (3-AMINOPIPERIDIN-1-YL) -5-OXO-1,2,4-TRIAZINE DERIVATIVES AS DIPEPTIDYL-PEPTIDASE IV (DPP IV) INHIBITORS
HUP1300733A2 (en) A method of preparing 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl- 4-yl)methyl)-1h-benzo[d]imidazole-7-carboxylates and conversion thereof to azilsartan
WO2011021224A3 (en) Improved process for preparing (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-(tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate
WO2011007368A3 (en) An improved process for preparation of olmesartan
EA200901295A1 (ru) Кристаллический 1-(циклогексилоксикарбонилокси)этил-1-((2`-цианодифенил-4-ил)метил)-2-этокси-1н-бензо[d]имидазол-7-карбоксилат и способ его получения